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Purpose: mpMRI has been demonstrated to be very useful for 
staging and surveillance of localized prostate cancer. The PiRads 
system has been developed for scoring the malignant probability 
of lesions. We identified the dominant intra-prostatic lesion (DIL) 
on mpMRI for intermediate- and high-risk prostate cancer before 
and 15 months after radiation to determine if the PiRads system 
could be useful in assessing the radiologic response to treatment. 
Methods and Materials: From August 2012 to July 2013, 26 
patients with predominantly unilateral disease consented to a 
University Ethics-approved Phase 2 study of selective dose 
escalation. HDR brachytherapy was performed in weeks 1 and 3 
of treatment, each delivering one fraction of 10 Gy to the whole 
prostate. External beam consisted of 46 Gy/23 fractions starting 
within one week after the first HDR fraction. Pre-treatment T2 
FSE images were obtained using 1.5T endorectal MRI in 
transverse, sagittal and coronal planes followed by Dynamic 
Contrast Enhancement after injection of gadolinium. Apparent 
Diffusion Coefficient maps were calculated. Following image 
registration, the DIL was transposed to the intra-operative TRUS 
with source-delivery catheters in place for the purpose of a 25% 
escalation in dose. At median 15.6 mo (12-18.6) mp MRI was 
repeated in the 16 patients who did not receive ADT. 
Results: Twenty-five out of 26 patients initially had a visible DIL. 
Mean pre-treatment PiRads score was 4.1 (range 3-5 for region 
of biopsy-proven disease). Coverage of the DIL was excellent 
with a median of 97% receiving the planned escalation of 25%. 
Mean PiRads score in follow up mpMRI in 16 patients at a median 
of 15 months post-treatment was 2.7. Median PSA was 0.2. Only 
two MRI’s still received a PiRads score of 4 and PSA for these two 
patients was 1.4 and 1.2; all others were < 0.5 ng/ml. Current 
PSA is 1.1 and 1.02 for these two patients and biopsies show 
scattered foci of residual tumour with marked RT effect. 
Conclusions: mpMRI using the PiRads classification may be 
adjunctive to PSA to assess response to radiation. Optimal timing 
and correlation with biopsy findings needs to be determined in a 
larger population. 
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Purpose: Moderate HypoRT is an acceptable option in the 
curative treatment of prostate cancer. Among different 
fractionation regimens, the dose of 60 Gy in 20 fractions 
was used in prospective randomized trials (PROFIT, CHiiP), 
mainly for low and intermediate-risk patients where the PTV 
is only the prostate(+/- seminal vesicle(SV) but not the 
pelvic nodes. We report here the acute and late toxicity in 
high-risk prostate cancer patients treated with androgen 
suppression and HypoRT to the prostate and pelvic nodes with 
doses of 60 Gy to prostate and 44 Gy to the pelvic nodes 
given in 20 fractions with a simultaneous integrated boost.  
Methods and Materials: Localized high-risk prostate 
cancer patients (T3, or PSA>20ng/ml, or GS >8) were 
treated with androgen suppression (6-24 months) started 2-3 
months before HypoRT. Radiotherapy was delivered using IMRT 
with daily IGRT. Constraints for organs at risk were the 
same of RTOG-0126 
corrected with the linear-quadratic model (α/β=3Gy). A dose of 
44 Gy (2.2 Gy/fraction) was delivered to the pelvic nodes and 60 
Gy (3 Gy/fraction) to the prostate (+/-SV) with a concomitant 
boost in 20 fractions (4 weeks). Cone beam CT was used daily to 
guide the treatment accuracy. Acute and late toxicities were 
assessed prospectively and scored using the National Cancer 
Institute Common Terminology Criteria for Adverse Events, 
version3.0. Biochemical failure was determined using the 
Phoenix definition. 
Results: 105 patients treated between September/2010 and 
November/2013 were reviewed. Median age, median initial PSA 
and T stage were 72 years (52-84), PSA=14(1.8-108), T1c = 36 and 
T3= 22 patients. Median follow up is 35 months (12-61). Acute GI 
toxicity (%) was as follows: Grade 0 = 38, Grade 1 = 45, Grade 2 
= 16 and Grade 3 = 1. Acute GU toxicity(%): Grade 0 = 32, Grade 
1 = 50, Grade 2 = 14 and Grade 3 = 3. The worst late GI toxicity(%) 
was, as follows: Grade 0 = 74 Grade 1 = 19, Grade 2/3 = 7. The 
worst late GU toxicity(%) was: Grade 0 = 77, Grade 1 = 15, Grade 
2/3 = 8. There was no Grade>3 toxicity. At the last follow-up the 
incidences of grade 2  late GU and GI toxicity were 5% and 3%, 
respectively (no residual grade >2 toxicity). At this limited 
follow-up, 13 patients developed biochemical failure at a median 
time of 27 months with 8 of them showing evidence of metastatic 
disease. Three patients died so far, and one from prostate 
cancer. 
Conclusion: Androgen suppression with moderate HypoRT IMRT 
and IGRT to the prostate (60Gy) and pelvic nodes (44Gy) 
delivered with simultaneous integrated boost in 4 weeks (20 
fractions) is feasible and well tolerated. Further follow-up is 
needed to establish long-term PSA control rates and survival 
outcomes.  
54  
A POPULATION-BASED STUDY OF RADIATION THERAPY REFERRAL 
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Purpose: Adjuvant radiotherapy (ART) post-radical 
prostatectomy (RP) has been shown to benefit patients with 
pathologic T3 or margin-positive prostate cancer. Early salvage 
radiotherapy (SRT) is commonly practiced, but it remains unclear 
if SRT confers equivalent outcomes to ART. Recent Ontario 
Practice Guidelines recommend referral to radiation oncology 
(RO) within six months of RP to discuss ART and SRT. Our 
objectives were to describe patterns of care over time to (1) 
assess post-RP referral patterns to RO; (2) describe ART and SRT 
utilization; and (3) compare time trends before and after seminal 
trials and guidelines were published, and in doing so, provide 
indications of access to quality care.  
Methods and Materials: This was a retrospective cohort study. 
Electronic clinic visit and RT treatment records were linked to 
the population-based Ontario Cancer Registry. The study 
population included all prostate cancer cases treated with RP in 
Ontario January 1, 2003 - November 30, 2012. ART was defined 
as curative RT within six months of RP, and SRT was 6 - 24 months 
post-RP. Changes in RO referral and RT rates over time were 
statistically analyzed using the Cochran-Mantel-Haenszel Chi-
Square test.  
Results: Over the study period, 30,447 prostate cancer patients 
received RP and 15.2% saw an RO within six months of RP. This 
proportion doubled between 2003 and 2012 (from 10.7% in 2003-
2004 to 21.7% in 2011-2012, p < 0.001 for trend). The annual 
percentage change was largest 2009-2011 (3.4% increase). In 
comparison, the proportion seen within 24 months of RP 
remained stable at 32.3% ± 1.4%. Amongst the 4,641 patients 
seen by an RO within 6 months of RP for consideration of ART or 
SRT, the proportion receiving ART remained relatively constant 
at 51.0% ± 3.0%. Commensurate with RO referral trends, there 
